Shared at the 2018 American Society of Bone and Mineral Research Meeting

We are pleased to share this news delivered by Blueprint Medicines last month in Montreal at the 2018 American Society of Bone and Mineral Research Meeting (ASBMR). The title of their talk was "BLU-782, a highly selective ALK2 inhibitor, designed to specifically target the cause of fibrodysplasia ossificans progressiva."